Psychiatry Research
July 1, 2026
Erin Artna, Guneet Sandhu, Noah Chisamore et al.
1 citation
Borderline personality disorder (BPD) is a serious mental illness with high rates of morbidity and stigma; however, successful remission is frequently limited by a paucity of accessible treatment options. In an era of growing interest in psychedelics as novel psychiatric treatment modalities, patients with BPD are often excluded from research due to perceived safety risks, particularly...
Multidisciplinary Collaborative Journal
July 1, 2026
Érika A. Chillogallo–torres, Marcos D. Calle‐morán, Karen P. Cando–andrade et al.
This research involved a literature review on the recreational, Western medicinal and ethnobotanical uses of hallucinogenic mushrooms. Search engines such as PubMed and Google Scholar, among others, and Boolean operators were used. A total of 60 scientific papers in both Spanish and English were analyzed. Since the 11th century, Japan has recorded the consumption of the butterfly mushroom,...
Neuropsychiatrie
June 30, 2026
Cielo A Estela-Fernandez, Reem Mohamed Yousif Elsheikh, Dal Bianco Beatrice et al.
Major depressive disorder (MDD) is a heterogeneous, debilitating disorder. A distinct subgroup within the MDD spectrum is identified to have treatment-resistant depression (TRD). There is an impetus to find alternative treatments for TRD to reduce disease burden and improve quality of life. Psychedelics have been used in the treatment of various psychiatric disorders since the 1950s, with...
Journal of Psychopharmacology
June 28, 2026
Yiğit Özaydın, Buket Canlan Özaydın
Background: Psychedelic microdosing—repeated sub-perceptual doses of lysergic acid diethylamide (LSD) or psilocybin—has attracted scientific interest as a potential mood and cognitive intervention. The evidence base remains methodologically heterogeneous and vulnerable to expectancy bias. Methods: We conducted an umbrella review with narrative synthesis following Joanna Briggs Institute...
International Journal of Molecular Sciences
June 26, 2026
M. Fernández‐guarino, Nicolás Yagüe-septién, Laura Marín-ochoa et al.
Recent evidence reveals that several psychotropic compounds exert significant biological effects on the skin through neurochemical and immunomodulatory pathways. Cannabinoids such as tetrahydrocannabinol (THC) show potent anti-inflammatory, antipruritic, and anti-aging properties when applied topically, and may hold therapeutic potential. Antidepressants, particularly fluoxetine (Prozac), have...
Journal of Psychopharmacology
June 25, 2026
Pavan S Brar, Rebecca B Price, Stephen Ross et al.
In the past decade, interest in studying psychedelic compounds as potential therapeutic agents has resurged. These studies carefully exclude individuals at risk for developing psychotic symptoms in response to psychedelic use. Given the potential for psychedelics to be established as treatments in psychiatry, it is important to more robustly understand their link with psychosis and...
Proceedings of the National Academy of Sciences
June 24, 2026
Yibo Wang, H Wang, C T Lin et al.
Natural hallucinogenic compounds have arisen independently across plants, fungi, and animals, evolving into a diverse chemical arsenal that includes phenethylamines, indolealkylamines, and terpenoid scaffolds. Beyond clinical and cultural frameworks, their ecological origins and evolutionary trajectories may help explain why such potent modulators of perception, emotion, and cognition persist...
Translational Psychiatry
June 24, 2026
Mauro Pettorruso, Giacomo D’andrea, Antonio Inserra et al.
Clinical trials investigating psychedelic compounds for depression and anxiety-related disorders are yielding promising preliminary results. Psychedelics produce profound alterations in brain function—such as suppression of the default mode network and thalamocortical dysregulation—leading to intense subjective experiences including ego dissolution and mystical-type states. While often...
June 19, 2026
Jules Evans, Christian Jurlando, David Luke et al.
preprint
Sorcery, black magic, and supernatural harm are central to many Amazonian shamanic traditions, yet their role in contemporary Western psychedelic culture has received little systematic empirical attention. Ethnographic work suggests that Western participants in ayahuasca tourism often downplay indigenous sorcery frameworks in favour of psychological or therapeutic interpretations of difficult...
ACS Chemical Neuroscience
June 17, 2026
Anoushka Bhat, Elmira Zolali, Mahfuz A Sakib et al.
Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...